admin

It has been known for some time that plants communicate with one another, but Israeli scientists now say they’ve identified “words,” and have found that different species speak in different “languages,” according to a groundbreaking new study published Thursday in the prestigious scientific journal Cell.

Scientists already know that plants communicate in a variety of ways when they are stressed. They might change physically (by wilting or changing leaf color), become bitter to the taste (to deter herbivores), or emit smells (volatile organic compounds) to tell other members of the family that they are under attack, for example by insects.

Image: Tomatoes were among the plants tested for sound by Tel Aviv University researchers. (David Besa, CC BY 2.0, Wikimedia Commons)

By Tom Still

MADISON, Wis. — Society has been here many times before. A little more than 200 years ago, a group of English textile workers called the Luddites took to destroying mill machinery — not because they were inherently anti-technology — but mainly to protest labor conditions at the time. The movement faded in a few years and the textile industry continued down an inevitable road to automation.

The history of technology reveals many such examples of innovation being met with suspicion and worries that mankind would lose its moral compass. From Gutenberg’s printing press to the dawn of the computer age, people have fretted that new ways and machines would erode the ability of people to discern good from bad while dangerously accelerating change.

$600,000 invested into 3 new ventures and $1.6Million awarded to 12 project grants

COLUMBIA, Md. (March 29, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent round of funding through the Maryland Innovation Initiative (MII).

Established in 2012, the MII program was created as a partnership between the State of Maryland and five Maryland academic research institutions: Johns Hopkins University; Morgan State University; University of Maryland, Baltimore; University of Maryland, Baltimore County; and University of Maryland, College Park. The program’s mission is to accelerate and support the commercialization of promising technologies from bench to market through investments in innovation, entrepreneurship and venture creation. 

When husband and wife Zairen Sun Ph.D. ’98 and Beibei Li Ph.D. ’98 arrived in College Park from China in 1992, they had little understanding of their new country or its traditions or practices. What they did have was a mentor at the University of Maryland who knew what it was like to be an immigrant to the U.S.—and who could empathize with the process of adjusting to a very different way of doing things.

• NARCAN® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening access
• Expected over-the-counter availability is anticipated by late summer of this year

GAITHERSBURG, Md., March 29, 2023 (GLOBE NEWSWIRE) — Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose. This decision comes at a time when approximately every eight minutes, a person dies from an opioid overdose and research shows the epidemic is escalating in the U.S. with the rise in synthetic opioids. By offering NARCAN® Nasal Spray as an OTC treatment, anyone will be able to access it without a prescription, which is an important step in the fight to reduce the number of opioid overdose deaths occurring each day.

MARCH 28, 2023 – GAITHERSBURG, Md., (BUSINESS WIRE) — Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd. The investment will be used to advance and accelerate lead candidate JK07, including the planned initiation of the first Phase 2 study in HFrEF, the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction (HFpEF), and the launch of the Company’s first neurology clinical trial with JK07. The financing will also support the ongoing Phase 1/2 trial of JK08 in solid tumors and advance JK06, a pre-clinical biparatopic antibody-drug conjugate, into an initial Phase 1/2 study.

Leiden, the Netherlands , March 28, 2023 / B3C newswire / — MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company. The partnership comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies.

Ready to explore the frontiers of cancer therapeutics? Discover how AUM Biosciences, with a key presence in Montgomery County, Maryland, in the BioHealth Capital Region, is revolutionizing the development of innovative oncology medicines and transforming the fight against cancer resistance. Join us on this episode of BioTalk with Rich Bendis as we chat with Vishal Doshi, Chairman & CEO of AUM Biosciences, a visionary leader in the biotech industry. Tune in to the conversation that’s sparking new hope in the battle against cancer.

Listen now via your favorite podcast platforms:
Apple – https://apple.co/42LvH4A Google – https://bit.ly/40yTOBC Spotify – https://spoti.fi/40F2NkV Amazon Music – https://amzn.to/40hFz4L TuneIn – https://bit.ly/42Gpfff YouTube – https://bit.ly/3TMIuji